- "
- "
( )
:
: ... .. .
" - .. ": .. .
" " : ..., ., -. .. , ..., . .. , ..., .. , ... .. .
1.
1.1. () () - .
1.2. () - () () "" . , "" ( ) "", , "", "", , . "", , .
, , - .
, : ; ; ; .
1.3. , , , , , .
1.4. " - " :
- " - ", ;
- ( ; .);
|
|
|
- .
1.5. " - " :
- ();
- ;
- , ;
- .
, . , . , : , , , , ..
, , . , - , .
.
1.6. , " - ", .
2.
- () " - "
2.1. , . 6 " - " (. 1).
1
- " - "
| , , . - | |
| , , , . | |
| , , - . | |
| , ; (, , ), | |
| , , , . , | |
| , , |
|
|
|
2.2. " - " , , . .
- " - " (. 2).
2
- " - "
| 1. | ? | +1 | ||
| 2. | () ? | +2 | -1 | |
| 3. | ( ) ? | +1 | ||
| 4. | ? | +2 | -1 | |
| 5. | ( ), ? | -1 | +2 | |
| 6. | ( ) , ? | +1 | ||
| 7. | ? | +1 | ||
| 8. | ? | +1 | ||
| 9. | ? | +1 | ||
| 10. | ? | -1 | +1 |
" - " 10 :
- 9 ;
- 5 - 8 ;
- 1 - 4 ;
- 0 .
2.2.1. - , ( ) (. 4).
4
KARCH F.E., LASAGNA L.
┌─────────────┬─────────────────────────────────────────────┬────┐
│ │ │-│
│ │ │ │
├─────────────┼─────────────────────────────────────────────┼────┤
│ │ │2 │
│ │, │1 │
│ │ │0 │
|
|
|
│ │ │-1 │
├─────────────┼─────────────────────────────────────────────┼────┤
│- │ │2 │
│ │ │1 │
│ │ │0 │
│ │ , │-1 │
│ │ │ │
├─────────────┼─────────────────────────────────────────────┼────┤
│ │ │2 │
│ │ │-2 │
│ │ , │1 │
│ │ │0 │
│ │ , │0 │
│ │ ( │1 │
│ │) │ │
├─────────────┼─────────────────────────────────────────────┼────┤
│ │ │3 │
│ │ │-1 │
│ │ │0 │
│-│ - │0 │
│ │ │ │
├─────────────┼─────────────────────────────────────────────┼────┤
│- │ │-3 │
│ │ │-1 │
││ │0 │
│ │ : │1 │
│ │- - , , ;│1 │
│ │- , , │1 │
│ │ │ │
└─────────────┴─────────────────────────────────────────────┴────┘
|
|
|
:
- 0 ;
- 1 - 3 ;
- 4 - 5 ;
- 6 - 7 ;
8 .
2.3. - " - " . .
2.3.1. , " ", (. 3).
3
" - ",
| - , | |
| , - , , , , - , | |
| , - - ( .) |
, , , .
2.3.2. Benichou - . - ", ". - :
- (, );
- ;
- ;
- ( );
- ;
- ;
- ", ", .
2.4. , . , , , , , - .
, . - .
, , " " .
" - ", , ", ", . , , .
3.
3.1. (pharmacoviqilance) - , , , , .
3.2. (adverse reaction) - , , - .
|
|
|
3.3. (adverse event) - , - . .
3.4. (serious adverse reaction) - , :
- ;
- , ;
- , ;
- ;
- ;
- (medically important or medically significant condition).
3.5. (unexpected adverse reaction) - , .
3.6. (verification) - , , , , . , , , .
3.7. - " - " - , .
3.8. - - , . . . "" - . , - (, ).
1. .., ..,
, , 2004 ., 200 .
2. .., . "
". , 2001 ., 150 .
3. .
. . I/ . .. , , 2007,
. 256.
4. .. . ., 2006.
5. Benichou C. Ed. Adverse drug reactions. A practical guide to diagnosis
and management. Chichester: John Wiley & Sons, 1994.
6. Edwards I.R., Lindquist M., Wiholm B.E., et al. Quality criteria for
early signals of possible adverse drug reactions. Lancet, 1990; 336:
156-8.
7. Girard M., Testing the methods of assessment for adverse drug
reactions. Adv. Drug React. At Pois. Rev. 1984; 4: 237-44.
8. Inmann W.H.W., Monitoring for drug safety. 2nd ed. Lancaster: MTP
Press. 1986.
9. Jones.J.K., Approaches to evaluating causation of suspected drug
reactions. In: Strom B.L., Velo G. Ed. Drug Epidemiology and
Postmarketing Surveillance. New York. Plenum Press. 1992; 103-13.
10. Johnson J.M., Reasonable possibility: causality and postmarketing
surveillance. Drug. Inf. J., 1992; 26: 553-8.
11. Karch F.E., Lasagna L., Towards the operational identification of
adverse drug reactions. Clin. Pharmacol. Ther., 1977; 21: 247-54.
12. Kramer M.S., Leventhal J.M., Hutchinson T.A., et al. An algorithm
for the operational assessment of adverse drug reactions. I.
Background, description and instructions for use. JAMA, 1979; 242:
623-31.
13. Lake-Bakaar G., Scheuer P.J., Sherlock S., Hepatic reactions
associated with ketoconazole in the United Kingdom. BMJ, 1987; 294:
419-2259.
14. Lanctat K.L., Naranjo C.A., Comparison of the Bayesian approach
and a simple algorithm for assessment of adverse drug events. Clin
Pharmacol. Ther., 1995; 58: 692-8.
15. Meyboom R.H.B., Hekster Y.A., Egberts A.C.G., et al. Causal or
casual? The role of causality assessment in pharmacovigilance. Drug
Saf., 1997; 17: 374-89.
16. Meyboom R.H.B., Royer R.R., Causality assessment in the European
Community. Pharmacoepidemiol. Drug Saf., 1992; 1: 87-97.
17. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating
the probability of adverse drug reactions. Clin. Pharmacol Ther.,
1981; 30: 239-45.
18. Ronald D. Mann, Elizabeth B. Andrews, Pharmacovigilance/Wiley; 2
edition, 2007, . 702.
19. Salama A., Muelier Eckhardt C., The role of metabolitespecific
antibodies in nomifensinedependent immune hemolytic anemia. N. Engl.
J. Med., 1985; 313: 469-74.
20. Stricker B.H.C., Blok A.P.R., Claas F.H.J., et al. Hepatic injury
associated with the use of nitrofurans: a clinico-pathological study
of 52 reported cases. Hepatology, 1988; 8: 559-606.
21. Stricker B.H.C., Blok A.P.R., Claas F.H.J., et al. Ketoconazole
hepatic injury. J. Hepatol, 1986; 3: 399-406.
22. Venuiet J., Berneker G.C., Ciucci A.G. (Eds), Assessing causes of
adverse drug reactions. Academic Press, London, 1982.
23. WHO Collaborating Centre for International Drug Monitoring, Uppsala,
Sweden. 14th Annual meeting of Participating National Centres,
Barcelona, September 30 - October 1, 1991.
